NCT04183881View on ClinicalTrials.gov

A Phase 4 Clinical Study of Brodalumab

PHASE4CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

July 4, 2016

Primary Completion Date

January 10, 2017

Study Completion Date

July 24, 2017

Conditions
Psoriasis VulgarisPsoriatic ArthritisPustular; Psoriasis, Palmaris Et PlantarisPsoriatic Erythroderma
Interventions
DRUG

Brodalumab 210mg SC

210 mg, subcutaneous dosing, every 2 weeks

Trial Locations (1)

Unknown

The Jikei University Scoole of Medicine, Tokyo

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04183881 - A Phase 4 Clinical Study of Brodalumab | Biotech Hunter | Biotech Hunter